Anti-IL-20 monoclonal antibody suppresses prostate cancer growth and bone osteolysis in murine models

Yu Hsiang Hsu, Cheng Ying Wu, Chung-Hsi Hsing, Wei Ting Lai, Li Wha Wu, Ming Shi Chang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Interleukin (IL)-20 is a proinflammatory cytokine in the IL-10 family. IL-20 is associated with tumor promotion in the pathogenesis of oral, bladder, and breast cancer. However, little is known about the role of IL-20 in prostate cancer. We hypothesize that IL-20 promotes the growth of prostate cancer cells. Immunohistochemical staining showed that IL-20 and its receptors were expressed in human PC-3 and LNCaP prostate cancer cell lines and in prostate tumor tissue from 40 patients. In vitro, IL-20 upregulated N-cadherin, STAT3, vimentin, fibronectin, RANKL, cathepsin G, and cathepsin K, and increased the migration and colony formation of prostate cancer cells via activated p38, ERK1/2, AKT, and NF-κB signals in PC-3 cells. We investigated the effects of anti-IL-20 monoclonal antibody 7E on prostate tumor growth in vivo using SCID mouse subcutaneous and intratibial xenograft tumor models. In vivo, 7E reduced tumor growth, suppressed tumor-mediated osteolysis, and protected bone mineral density after intratibial injection of prostate cancer cells. We conclude that IL-20 is involved in the cell migration, colony formation, and tumor-induced osteolysis of prostate cancer. Therefore, IL-20 might be a novel target for treating prostate cancer.

Original languageEnglish
Article numbere0139871
JournalPLoS One
Volume10
Issue number10
DOIs
Publication statusPublished - Oct 6 2015

Fingerprint

Bone Neoplasms
Osteolysis
prostatic neoplasms
interleukins
monoclonal antibodies
Prostatic Neoplasms
Bone
animal models
Tumors
Monoclonal Antibodies
bones
Growth
Cells
Neoplasms
neoplasms
Prostate
cathepsin G
Cathepsin K
Cathepsin G
cathepsin K

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hsu, Y. H., Wu, C. Y., Hsing, C-H., Lai, W. T., Wu, L. W., & Chang, M. S. (2015). Anti-IL-20 monoclonal antibody suppresses prostate cancer growth and bone osteolysis in murine models. PLoS One, 10(10), [e0139871]. https://doi.org/10.1371/journal.pone.0139871

Anti-IL-20 monoclonal antibody suppresses prostate cancer growth and bone osteolysis in murine models. / Hsu, Yu Hsiang; Wu, Cheng Ying; Hsing, Chung-Hsi; Lai, Wei Ting; Wu, Li Wha; Chang, Ming Shi.

In: PLoS One, Vol. 10, No. 10, e0139871, 06.10.2015.

Research output: Contribution to journalArticle

Hsu, Yu Hsiang ; Wu, Cheng Ying ; Hsing, Chung-Hsi ; Lai, Wei Ting ; Wu, Li Wha ; Chang, Ming Shi. / Anti-IL-20 monoclonal antibody suppresses prostate cancer growth and bone osteolysis in murine models. In: PLoS One. 2015 ; Vol. 10, No. 10.
@article{8e1d6508de104d69ad37a767a31049fa,
title = "Anti-IL-20 monoclonal antibody suppresses prostate cancer growth and bone osteolysis in murine models",
abstract = "Interleukin (IL)-20 is a proinflammatory cytokine in the IL-10 family. IL-20 is associated with tumor promotion in the pathogenesis of oral, bladder, and breast cancer. However, little is known about the role of IL-20 in prostate cancer. We hypothesize that IL-20 promotes the growth of prostate cancer cells. Immunohistochemical staining showed that IL-20 and its receptors were expressed in human PC-3 and LNCaP prostate cancer cell lines and in prostate tumor tissue from 40 patients. In vitro, IL-20 upregulated N-cadherin, STAT3, vimentin, fibronectin, RANKL, cathepsin G, and cathepsin K, and increased the migration and colony formation of prostate cancer cells via activated p38, ERK1/2, AKT, and NF-κB signals in PC-3 cells. We investigated the effects of anti-IL-20 monoclonal antibody 7E on prostate tumor growth in vivo using SCID mouse subcutaneous and intratibial xenograft tumor models. In vivo, 7E reduced tumor growth, suppressed tumor-mediated osteolysis, and protected bone mineral density after intratibial injection of prostate cancer cells. We conclude that IL-20 is involved in the cell migration, colony formation, and tumor-induced osteolysis of prostate cancer. Therefore, IL-20 might be a novel target for treating prostate cancer.",
author = "Hsu, {Yu Hsiang} and Wu, {Cheng Ying} and Chung-Hsi Hsing and Lai, {Wei Ting} and Wu, {Li Wha} and Chang, {Ming Shi}",
year = "2015",
month = "10",
day = "6",
doi = "10.1371/journal.pone.0139871",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Anti-IL-20 monoclonal antibody suppresses prostate cancer growth and bone osteolysis in murine models

AU - Hsu, Yu Hsiang

AU - Wu, Cheng Ying

AU - Hsing, Chung-Hsi

AU - Lai, Wei Ting

AU - Wu, Li Wha

AU - Chang, Ming Shi

PY - 2015/10/6

Y1 - 2015/10/6

N2 - Interleukin (IL)-20 is a proinflammatory cytokine in the IL-10 family. IL-20 is associated with tumor promotion in the pathogenesis of oral, bladder, and breast cancer. However, little is known about the role of IL-20 in prostate cancer. We hypothesize that IL-20 promotes the growth of prostate cancer cells. Immunohistochemical staining showed that IL-20 and its receptors were expressed in human PC-3 and LNCaP prostate cancer cell lines and in prostate tumor tissue from 40 patients. In vitro, IL-20 upregulated N-cadherin, STAT3, vimentin, fibronectin, RANKL, cathepsin G, and cathepsin K, and increased the migration and colony formation of prostate cancer cells via activated p38, ERK1/2, AKT, and NF-κB signals in PC-3 cells. We investigated the effects of anti-IL-20 monoclonal antibody 7E on prostate tumor growth in vivo using SCID mouse subcutaneous and intratibial xenograft tumor models. In vivo, 7E reduced tumor growth, suppressed tumor-mediated osteolysis, and protected bone mineral density after intratibial injection of prostate cancer cells. We conclude that IL-20 is involved in the cell migration, colony formation, and tumor-induced osteolysis of prostate cancer. Therefore, IL-20 might be a novel target for treating prostate cancer.

AB - Interleukin (IL)-20 is a proinflammatory cytokine in the IL-10 family. IL-20 is associated with tumor promotion in the pathogenesis of oral, bladder, and breast cancer. However, little is known about the role of IL-20 in prostate cancer. We hypothesize that IL-20 promotes the growth of prostate cancer cells. Immunohistochemical staining showed that IL-20 and its receptors were expressed in human PC-3 and LNCaP prostate cancer cell lines and in prostate tumor tissue from 40 patients. In vitro, IL-20 upregulated N-cadherin, STAT3, vimentin, fibronectin, RANKL, cathepsin G, and cathepsin K, and increased the migration and colony formation of prostate cancer cells via activated p38, ERK1/2, AKT, and NF-κB signals in PC-3 cells. We investigated the effects of anti-IL-20 monoclonal antibody 7E on prostate tumor growth in vivo using SCID mouse subcutaneous and intratibial xenograft tumor models. In vivo, 7E reduced tumor growth, suppressed tumor-mediated osteolysis, and protected bone mineral density after intratibial injection of prostate cancer cells. We conclude that IL-20 is involved in the cell migration, colony formation, and tumor-induced osteolysis of prostate cancer. Therefore, IL-20 might be a novel target for treating prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84947997961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947997961&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0139871

DO - 10.1371/journal.pone.0139871

M3 - Article

C2 - 26440411

AN - SCOPUS:84947997961

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0139871

ER -